Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rhinitis, Allergic, Perennial Clear all
Completed No phase listed Observational

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

NCT00405899
View directory record Official record
Conditions
Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2010 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Fluticasone Nasal Spray Patient Preference Study

NCT00398476
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
fluticasone propionate (FP), fluticasone furoate (FF)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Fountain Valley, California • Long Beach, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

NCT00116883
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X aqueous nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

NCT02709538
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jun 10, 2026, 8:49 PM EDT
Completed No phase listed Observational

Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

NCT01632540
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
Beclomethasone Dipropionate (BDP) Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
46
States / cities
Little Rock, Alaska • Phoenix, Arizona • Encinitas, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Results available

Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium

NCT01221285
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
German cockroach (Blattella germanica) allergenic extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

NCT00894231
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
levocetirizine (Xyzal), placebo
Drug
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Jun 10, 2026, 8:49 PM EDT
Not listed Not applicable Interventional

Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis

NCT04024033
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
pine cone extract, placebo
Dietary Supplement · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

NCT00346775
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate, Flunisolide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
7
States / cities
Fresno, California • Napa, California • Roseville, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional

Perennial Allergic Rhinitis Study In Pediatric Subjects

NCT00108914
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 12 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Costa Mesa, California • Cudahy, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 4 Interventional

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

NCT00806754
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide nasal spray + placebo Azelastine, Ciclesonide nasal spray + Azelastine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Encinitas, California • Los Angeles, California • Mission Viejo, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Adults Sensitized to Cat

NCT00689299
View directory record Official record
Conditions
Allergy
Interventions
Standardized Allergenic Extract, Cat Hair, Placebo
Biological
Lead sponsor
Antigen Laboratories, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Marietta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Jun 10, 2026, 8:49 PM EDT
Completed No phase listed Observational

Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study

NCT00598780
View directory record Official record
Conditions
Rhinitis Allergic, Persistent
Interventions
Not listed
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years and older
Enrollment
7,870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Smyrna, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Jun 10, 2026, 8:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Efficacy & Safety of the UAS Immunotherapy Protocol

NCT01699659
View directory record Official record
Conditions
Perennial Allergic Rhinitis With Seasonal Variation
Interventions
allergen immunotherapy
Other
Lead sponsor
United Allergy Services
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

NCT01401465
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide, mometasone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
Huntington Beach, California • Mission Veijo, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 4 Interventional Results available

NasoNeb Delivery of an Intranasal Steroid

NCT01270256
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional

Seasonal Allergic Rhinitis In Pediatric Subjects

NCT00107757
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 12 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
65
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

NCT02443805
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Interventions
300 IR, Placebo
Biological
Lead sponsor
Stallergenes Greer
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 4 Interventional Results available

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

NCT00449072
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Placebo, TAA-AQ, Nasacort® AQ, Claritin®
Other · Drug
Lead sponsor
Sanofi
Industry
Eligibility
3 Years to 9 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Jun 10, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Jun 10, 2026, 8:49 PM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 10, 2026, 8:49 PM EDT